BTK
Les inhibiteurs de la tyrosine kinase de Bruton (BTK) sont des composés qui ciblent spécifiquement et inhibent la BTK, une enzyme cruciale impliquée dans la signalisation du récepteur des cellules B et la régulation de l'angiogenèse. La BTK joue un rôle significatif dans la prolifération et la survie des cellules cancéreuses, en particulier dans les malignités hématologiques. En inhibant la BTK, ces composés peuvent perturber l'angiogenèse et la croissance tumorale, ce qui les rend précieux en thérapie anticancéreuse. Chez CymitQuimica, nous offrons une gamme d'inhibiteurs de la BTK de haute qualité pour soutenir vos recherches en oncologie, immunologie et angiogenèse.
169 produits trouvés pour "BTK".
Trier par
Degré de pureté (%)
0
100
|
0
|
50
|
90
|
95
|
100
BMS-935177
CAS :BMS-935177 is a reversible BTK inhibitor with IC50 value of 3 nM.Formule :C31H26N4O3Degré de pureté :99.89%Couleur et forme :SolidMasse moléculaire :502.56BTK-IN-6
BTK-IN-6, a potent BTK inhibitor, may treat immune, cardiac, cancer, viral, inflammatory, metabolic, and neurological disorders.Formule :C23H22FN5O3Couleur et forme :SolidMasse moléculaire :435.45BTK-IN-32
CAS :BTK-IN-32 (compound C2) acts as a potent BTK inhibitor. Unlike isolated kinase domains, this compound activates full-length BTK as well as its smaller multidomain fragments [1].Formule :C35H35ClN4O3SCouleur et forme :SolidMasse moléculaire :627.2GNE-431
CAS :GNE-431: potent, selective noncovalent Btk inhibitor, IC50=3.2 nM; effective against C481R, T474I, T474M mutants, may counter ibrutinib resistance.Formule :C30H32N10O2Couleur et forme :SolidMasse moléculaire :564.64UBX-382
CAS :UBX-382 is an orally administered proteolysis-targeting chimera (PROTAC) designed to target BTK and disrupt B-cell receptor signaling. It demonstrates enhanced degradation of both wild-type and mutant BTK proteins, exhibiting anti-cancer effects in murine xenograft models using TMD-8 cells [1].Formule :C42H44N10O4Couleur et forme :SolidMasse moléculaire :752.86JAK3/BTK-IN-4
CAS :JAK3/BTK-IN-4, a dual inhibitor for JAK3/BTK, shows synergy in autoimmune disease treatment. (Patent WO2021147953A1, compound 003)Formule :C21H25ClN8OCouleur et forme :SolidMasse moléculaire :440.93BTK-IN-38
CAS :BTK-IN-38 (Example 125) is an efficacious inhibitor of BTK. It effectively suppresses the proliferation of DOHH2 and BT474 cells, with IC50 values of 114 nM and 340 nM, respectively.Formule :C27H26F2N4O2Couleur et forme :SolidMasse moléculaire :476.52WS-11
CAS :WS-11 is a non-covalent reversible inhibitor of BTK, with IC50 values of 3.9 nM for the wild-type and 2.2 nM for the C481S mutant BTK. In addition to strong hydrogen bonding, WS-11 also forms robust π-π interactions with PHE540, and p-π interactions with LYS430 within the active pocket.Formule :C26H22FN9O2Couleur et forme :SolidMasse moléculaire :511.51BMS-986143
CAS :BMS-986143: oral BTK inhibitor, IC50=0.26 nM, potential for autoimmune research, also targets TEC, BLK, BMX, TXK, YES1, ITK.Formule :C31H24Cl2N4O4Couleur et forme :SolidMasse moléculaire :587.45BTK degrader-1 intermediate
CAS :BTKdegrader-1 intermediate (compound 5) is a precursor in the synthesis of BTKdegrader-1, which serves as a toxin for Antibody-drug Conjugates (ADC) used in developing related molecules.Formule :C40H44F2N6O2Couleur et forme :SolidMasse moléculaire :678.81CFON-026
CAS :CFON-026 is a selective, orally active, non-covalent BTK inhibitor with an IC50 of 0.27 nM. It demonstrates significant antitumor activity against wild-type BTK (TMD8 and REC-1) as well as all clinically relevant BTK resistance mutations (BTKC481S, T474I, L528W, and V416L). CFON-026 induces complete tumor regression in the TMD8 xenograft mouse model. This compound is applicable for research into hematologic cancers, such as chronic lymphocytic leukemia and Waldenström's macroglobulinemia.Formule :C33H34N8O2Masse moléculaire :574.68RET-IN-14
CAS :RET-IN-14 inhibits RET (IC50: <0.51-9.3 nM) & BTK (C481S) (IC50: 9.2-15 nM), promising for tumor research.Formule :C24H23FN8O4Couleur et forme :SolidMasse moléculaire :506.49BIIB129
CAS :BIIB129 is a selective and brain-penetrant BTK covalent inhibitor used to study B-cell proliferation-related diseases.Formule :C19H22N6O2Degré de pureté :98.56%Couleur et forme :Yellow SolidMasse moléculaire :366.42BTK-IN-8
BTK-IN-8: potent, selective covalent BTK inhibitor; IC50=0.22 nM, Kd=0.91 nM; effective in blood CD69 cells (IC50=0.029 μM).Formule :C26H36N6O3Couleur et forme :SolidMasse moléculaire :480.6BTK-IN-15
BTK-IN-15: Oral BTK inhibitor, IC50 0.7 nM, induces cancer cell apoptosis, selective with anti-tumor effects.Formule :C28H24FN5O2Couleur et forme :SolidMasse moléculaire :481.52Birelentinib
CAS :Birelentinib (Birelentinib) is an inhibitor of both wild-type and mutant BTK with IC₅₀ values of 6.72 and 6.11 nM, respectively.Formule :C23H21F2N5O3Degré de pureté :99.36% - 99.78%Masse moléculaire :453.44GDC-0834 S-enantiomer
CAS :GDC-0834, the S-enantiomer, is a potent and selective inhibitor of Bruton's tyrosine kinase (BTK).Formule :C33H36N6O3SDegré de pureté :98%Couleur et forme :SolidMasse moléculaire :596.74BTK-IN-10
CAS :BTK-IN-10 is a potent inhibitor of BTK, acting on wild-type BTK (IC50<5 nM) or mutant BTK (C481S) (IC50<5 nM).Formule :C25H24F2N4O2Couleur et forme :SolidMasse moléculaire :450.48JAK3/BTK-IN-3
CAS :JAK3/BTK-IN-3: strong dual JAK3/BTK suppressor, promising for autoimmune disease research.Formule :C22H28N8OCouleur et forme :SolidMasse moléculaire :420.51BTK inhibitor 18
BTK inhibitor 18 is a selective, potent, covalent, orally active Btk inhibitor (IC50: 142 nM) that exhibits anti-inflammatory effects.Formule :C29H25N5O4S2Couleur et forme :SolidMasse moléculaire :571.67
